the work is mostly on okazaki fragments, but a major conclusion from my phd thesis was that B-RNA is stuck because of a very low probability event (the breaking of a large number of hbonds simultaneously).
http://scholar.google.com/citations?view_op=view_citation&hl...
http://scholar.google.com/citations?view_op=view_citation&hl...
http://scholar.google.com/citations?view_op=view_citation&hl...
http://scholar.google.com/citations?view_op=view_citation&hl...
Remember, the patent is a MOLECULE patent, not a PROCESS patent.
Anyway, your comment about oncogenes again shows you haven't read Biology of Cancer. if you read the first four chapters, it works out the history through which we worked out the understand of oncogenes. And the history is different from what we know now to be the prevalent mechanisms. The use of tumor viruses, which is nicely explained, demonstrates that scientists had already described the phenomenon I'm cited in the mid-1970's. That phenomenon wasn't really followed up on after the mid-80s, when people got better mechanisms and a larger understanding of cancer. But if you go back to the tumor virus literature and really understand it at a fundamental level, you have to acknowledge that BRCA cDNAs identical to the Myriad patent have almost certainly existed in both free (nucleoplasm) and integrated forms in at least one cell in the past. Whether that cell survived, is irrelevant.
Finally, if you think an existence proof is going to break a patent, I wish you luck in your future pursuits in life.
See the first 4 chapters of "Biology of Cancer" by Weinberg.